SEC Form 10-Q filed by Eterna Therapeutics Inc.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State of incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
Large accelerated filer
|
☐ |
Accelerated filer
|
☐
|
|
☒ |
Smaller reporting company
|
|
Emerging growth company
|
Page
|
||
PART I – FINANCIAL INFORMATION
|
||
Item 1.
|
Financial Statements (unaudited)
|
|
1 | ||
2 | ||
3 | ||
4 | ||
5
|
||
Item 2.
|
20 | |
Item 3.
|
27 | |
Item 4.
|
27 | |
PART II – OTHER INFORMATION
|
||
Item 1.
|
28 | |
Item 1A.
|
28 |
|
Item 2.
|
30 | |
Item 3.
|
30 | |
Item 4.
|
30 | |
Item 5.
|
30 | |
Item 6.
|
31 | |
32 |
This Quarterly Report on Form 10-Q contains “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 (“PSLRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements related to future events, results, performance, prospects and opportunities, including statements related to our strategic plans, capital needs, and our financial position. Forward-looking statements are based on information currently available to us, on our current expectations, estimates, forecasts, and projections about the industries in which we operate and on the beliefs and assumptions of management. Forward looking statements often contain words such as “expects,” “anticipates,” “could,” “targets,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “would,” and similar expressions. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, and other characterizations of future events or circumstances, are forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. For us, particular factors that might cause or contribute to such differences include those risks and uncertainties described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2024, in Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q, and in other documents we file from time to time with the SEC.
Readers are urged not to place undue reliance on the forward-looking statements in this Quarterly Report on Form 10-Q, which speak only as of the date of this Quarterly Report on Form 10-Q. We are including this cautionary note to make applicable, and take advantage of, the safe harbor provisions of the PSLRA. Except as required by law, we do not undertake, and expressly disclaim any obligation, to disseminate, after the date hereof, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.
We believe that the expectations reflected in forward-looking statements in this Quarterly Report on Form 10-Q are based upon reasonable assumptions at the time made. However, given the risks and uncertainties, you should not rely on any forward-looking statements as a prediction of actual results, developments or other outcomes. You should read these forward-looking statements with the understanding that we may be unable to achieve projected results, developments or other outcomes and that actual results, developments or other outcomes may be materially different from what we expect.
Unless stated otherwise or the context otherwise requires, all references in this Quarterly Report on Form 10-Q to “Eterna” refer to Eterna Therapeutics Inc., references to “Eterna LLC” refer to Eterna Therapeutics LLC, a wholly owned subsidiary of Eterna, and references to the “Company,” “we,” “us” or “our” refer to Eterna and its subsidiaries, including Eterna LLC, Novellus, Inc. and Novellus Therapeutics Limited.
March 31, | December 31, | |||||||
2024
|
2023
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Other receivables
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Restricted cash
|
||||||||
Property and equipment, net
|
|
|
||||||
Right-of-use assets - operating leases
|
|
|
||||||
Goodwill
|
|
|
||||||
Other assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
|
$
|
|
||||
Accrued expenses
|
|
|
||||||
Income taxes payable
|
||||||||
Operating lease liabilities, current
|
|
|
||||||
Due to , current
|
||||||||
Deferred revenue, current
|
||||||||
Total current liabilities
|
|
|
||||||
Convertible notes, net
|
||||||||
Warrant liabilities
|
|
|
||||||
Operating lease liabilities, non-current
|
|
|
||||||
Deferred revenue, non-current
|
||||||||
Contingent consideration liability
|
||||||||
Other liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
Stockholders’ (deficit) equity:
|
||||||||
Preferred stock, $
|
||||||||
Common stock, $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Total stockholders’ (deficit) equity
|
(
|
)
|
|
|||||
Total liabilities and stockholders’ (deficit) equity
|
$
|
|
$
|
|
Three months ended March 31, | ||||||||
2024
|
2023
|
|||||||
Revenue
|
$ | $ | ||||||
Cost of revenues
|
||||||||
Gross loss
|
( |
) | ( |
) | ||||
Operating expenses:
|
||||||||
Research and development
|
|
|
||||||
General and administrative
|
|
|
||||||
Total operating expenses
|
|
|
||||||
Loss from operations
|
(
|
)
|
(
|
)
|
||||
Other expense, net:
|
||||||||
Change in fair value of warrant liabilities
|
( |
) | ( |
) | ||||
Loss on non-controlling investment
|
( |
) | ||||||
Interest (expense) income, net | ( |
) | ||||||
Total other expense, net
|
(
|
)
|
(
|
)
|
||||
Loss before income taxes
|
( |
) | ( |
) | ||||
Provision for income taxes
|
( |
) | ( |
) | ||||
Net loss
|
|
(
|
)
|
|
(
|
)
|
||
Net loss per common share - basic and diluted | $ | ( |
) | $ | ( |
) | ||
Weighted average shares outstanding - basic and diluted
|
|
|
Series A Preferred | Additional Paid- | |||||||||||||||||||||||||||
|
Stock
|
Common Stock
|
in
|
Accumulated | ||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
|||||||||||||||||||||
Balances at January 1, 2024
|
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||
Issuance of note warrants
|
- | - | ||||||||||||||||||||||||||
Costs allocated to note warrants |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||
Stock-based compensation
|
- | - | ||||||||||||||||||||||||||
Net loss
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||
Balances at March 31, 2024
|
$ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||
|
||||||||||||||||||||||||||||
Balances at January 1, 2023
|
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||
Stock-based compensation
|
- | - | ||||||||||||||||||||||||||
Net loss
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||
Balances at March 31, 2023
|
$ | $ | $ | $ | ( |
) | $ |
For the three months ended | ||||||||
|
March 31,
|
|||||||
|
2024
|
2023
|
||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
|
|
||||||
Stock-based compensation
|
|
|
||||||
Amortization of right-of-use asset
|
|
|
||||||
Gain on disposal of fixed assets
|
( |
) | ||||||
Accrued interest expense
|
||||||||
Paid-in-kind interest expense
|
||||||||
Amortization of debt discount and debt issuance costs
|
||||||||
Change in fair value of warrant liabilities
|
||||||||
Loss on non-controlling investment
|
|
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Other receivables
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Other non-current assets
|
|
(
|
)
|
|||||
Accounts payable and accrued expenses
|
|
(
|
)
|
|||||
Operating lease liability
|
|
(
|
)
|
|||||
Due to related party
|
( |
) | ( |
) | ||||
Deferred revenue
|
( |
) | ||||||
Other liabilities
|
|
(
|
)
|
|||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
(
|
)
|
|
|||||
Proceeds received from the sale of fixed assets
|
||||||||
Net cash used in investing activities
|
(
|
)
|
|
|||||
Cash flows from financing activities:
|
||||||||
Proceeds received from the convertible notes financing
|
||||||||
Fees paid related to the convertible notes financing
|
( |
) | ||||||
Net cash provided by financing activities
|
|
|
||||||
Net decrease in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
Cash, cash equivalents and restricted cash at beginning of period
|
|
|
||||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
|
$
|
|
||||
|
||||||||
Supplemental disclosures of cash flow information:
|
||||||||
Cash paid during the period for:
|
||||||||
Interest
|
$
|
|
$
|
|
||||
Income taxes
|
$ | $ | ||||||
Supplemental disclosure of non-cash investing and financing activities:
|
||||||||
Note warrants issued
|
$ | $ | ||||||
Unpaid fees incurred in connection with the convertible notes financing
|
$ | $ | ||||||
Paid in-kind interest added to convertible notes principal
|
$ | $ | ||||||
Adjustment to lease liability and ROU asset due to remeasurement
|
$ | $ | ||||||
Property and equipment purchased but not paid
|
$ | $ | ||||||
Reconciliation of cash, cash equivalents and restricted cash at end of period:
|
||||||||
Cash and cash equivalents
|
$ | $ | ||||||
Restricted Cash
|
||||||||
Total Cash, cash equivalents and restricted cash at end of period
|
$ | $ |
1) |
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
|
2) |
LIQUIDITY AND CAPITAL RESOURCES
|
3)
|
CONTRACT WITH CUSTOMER
|
4)
|
CONVERTIBLE NOTES FINANCINGS
|
|
Allocation of Proceeds and Costs
|
Allocation of
|
||||||||||||||||||
|
Relative
Fair Value |
Allocation
Percentage |
Proceeds
|
Costs
|
Proceeds,
Net |
|||||||||||||||
Convertible notes
|
$
|
|
|
%
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
Note warrants
|
|
|
%
|
|
(
|
)
|
|
|||||||||||||
|
$
|
|
|
%
|
$
|
|
$
|
(
|
)
|
$
|
|
|
Stock
Price |
Credit
Spread |
Volatility
|
Risk-Free
Rate |
||||||||||||
Convertible notes
|
$
|
|
|
|
%
|
|
%
|
|
Stock
Price |
Exercise
Price |
Expected
Life |
Volatility
|
Dividend
|
Risk-Free
Rate |
|||||||||||||||
Warrants
|
$
|
|
$
|
|
|
|
%
|
|
%
|
|
%
|
|
Gross
convertible
notes
|
Debt
discount
and debt
issuance
costs
|
Convertible
notes, net
|
|||||||||
|
||||||||||||
Beginning balanace as of January 1, 2024
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
December 2023 notes issued in January 2024
|
|
(
|
)
|
|
||||||||
Paid-in-kind interest added to principal
|
|
-
|
|
|||||||||
Amortization of debt discount and debt issuance costs
|
-
|
|
|
|||||||||
Ending balanace as of March 31, 2024
|
$
|
|
$
|
(
|
)
|
$
|
|
5) |
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
• |
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
date.
|
• |
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might
include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or
liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
|
• |
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
|
Description
|
Level
|
March 31,
2024
|
December 31,
2023
|
|||||||||
Liabilities:
|
||||||||||||
Warrant liabilities - Q1-22 warrants
|
3
|
$ |
|
$ |
|
|||||||
Market cap contingent consideration |
3 |
$ |
$ |
|
Warrant
Liabilities
|
Contingent
Consideration
|
||||||
Fair value at January 1, 2024
|
$
|
|
$ | |||||
Change in fair value
|
|
|
||||||
Fair value at March 31, 2024
|
$
|
|
$ |
March 31, 2024
|
December 31, 2023 | |||||||||||||||||||
|
Level |
Carrying
Value
|
Fair
Value
|
Carrying
Value
|
Fair
Value
|
|||||||||||||||
Convertible notes
|
3 |
$
|
|
$
|
|
$ |
$ |
6) |
GOODWILL
|
7)
|
LEASES
|
Three months ended March 31,
|
||||||||
2024 |
2023 |
|||||||
Operating lease expense
|
$
|
|
$
|
|
||||
Sublease income
|
(
|
)
|
(
|
)
|
||||
Variable lease expense
|
|
|
||||||
Total lease expense
|
$
|
|
$
|
|
Operating Lease
ROU Assets
|
||||
Operating lease ROU assets at January 1, 2024
|
$
|
|
||
Adjustment to ROU asset for remeasurement of Somerville Sublease liability
|
||||
Amortization of operating lease ROU assets
|
(
|
)
|
||
Operating lease ROU assets at March 31, 2024
|
$
|
|
Operating Lease
Liabilities
|
||||
Operating lease liabilities at January 1, 2024
|
$
|
|
||
Adjustment to lease liablity due to remeasurement of Somerville Sublease
|
||||
Accretion of interest for Somerville Sublease
|
||||
Principal payments on operating lease liabilities
|
(
|
)
|
||
Operating lease liabilities at March 31, 2024
|
|
|||
Less non-current portion
|
|
|||
Current portion at March 31, 2024
|
$
|
|
As of
March 31,
2024
|
||||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
2028
|
|
|||
Thereafter
|
|
|||
Total payments
|
|
|||
Less imputed interest
|
(
|
)
|
||
Total operating lease liabilities
|
$
|
|
8)
|
ACCRUED EXPENSES
|
March 31,
2024 |
December 31,
2023
|
|||||||
Convertible notes interest
|
$ | $ | ||||||
Legal fees and related
|
|
|
||||||
Somerville facility
|
|
|
||||||
Professional fees
|
|
|
||||||
Accrued compensation
|
|
|
||||||
Other
|
|
|
||||||
Total accrued expenses
|
$
|
|
$
|
|
9) |
RELATED PARTY TRANSACTIONS
|
Q4-22 PIPE
10) |
COMMITMENTS AND CONTINGENCIES
|
11) |
STOCK-BASED COMPENSATION
|
|
Three months ended March 31,
|
|||||||
|
2024
|
2023
|
||||||
Stock options granted
|
|
|
Three months ended March 31, | ||||||||
|
2024
|
2023
|
||||||
Weighted average risk-free rate
|
|
%
|
|
%
|
||||
Weighted average volatility
|
|
%
|
|
%
|
||||
Dividend yield
|
|
%
|
|
%
|
||||
Expected term
|
|
|
|
Three months ended March 31,
|
|||||||
|
2024
|
2023
|
||||||
Research and development
|
$
|
|
$
|
|
||||
General and administrative
|
|
|
||||||
Total
|
$
|
|
$
|
|
12) |
WARRANTS
|
|
Warrants
Outstanding (in thousands) |
Exercise
Price |
Expiration
Date |
Classification
|
|||||||
Q1-22 warrants | $ |
Liability |
|||||||||
Q4-22 warrants |
$ |
Equity |
|||||||||
July 2023 note warrants |
$ |
Equity | |||||||||
December 2023 note warrant issued December 15, 2023 |
$ | Equity | |||||||||
December 2023 note warrant issued January 11, 2024 |
$ | Equity |
|||||||||
13) |
NET LOSS PER SHARE
|
Three months ended March 31,
|
||||||||
2024
|
2023
|
|||||||
Warrants
|
|
|
||||||
Convertible Notes converted into common stock |
||||||||
Stock options
|
|
|
||||||
Preferred stock converted into common stock
|
|
|
||||||
RSUs
|
|
|
||||||
Total potential common shares excluded from computation
|
|
|
14) |
RECENT ACCOUNTING PRONOUNCEMENTS
|
15) |
SUBSEQUENT EVENTS
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
Three months ended March 31,
|
||||||||||||
(In thousands)
|
2024
|
2023
|
Change
|
|||||||||
Revenue
|
$
|
47
|
$
|
-
|
$
|
47
|
||||||
Cost of revenues
|
61
|
50
|
11
|
|||||||||
Gross loss
|
(14
|
)
|
(50
|
)
|
36
|
|||||||
Operating expenses:
|
||||||||||||
Research and development
|
1,458
|
1,674
|
(216
|
)
|
||||||||
General and administrative
|
4,315
|
3,592
|
723
|
|||||||||
Total operating expenses
|
5,773
|
5,266
|
507
|
|||||||||
Loss from operations
|
(5,787
|
)
|
(5,316
|
)
|
(471
|
)
|
||||||
Other expense, net:
|
||||||||||||
Change in fair value of warrant liabilities
|
(70
|
)
|
(45
|
)
|
(25
|
)
|
||||||
Loss on non-controlling investment
|
-
|
(51
|
)
|
51
|
||||||||
Interest (expense) income, net
|
(786
|
)
|
1
|
(787
|
)
|
|||||||
Total other expense, net
|
(856
|
)
|
(95
|
)
|
(761
|
)
|
||||||
-
|
||||||||||||
Loss before income taxes
|
(6,643
|
)
|
(5,411
|
)
|
(1,232
|
)
|
||||||
Provision for income taxes
|
(4
|
)
|
(5
|
)
|
1
|
|||||||
Net loss
|
$
|
(6,647
|
)
|
$
|
(5,416
|
)
|
$
|
(1,231
|
)
|
Three months ended March 31,
|
||||||||||||
2024
|
2023
|
Change
|
||||||||||
(in thousands)
|
||||||||||||
Professional fees
|
$
|
103
|
$
|
280
|
$
|
(177
|
)
|
|||||
Stock-based compensation
|
46
|
64
|
(18
|
)
|
||||||||
Payroll-related
|
325
|
203
|
122
|
|||||||||
MSA fees
|
812
|
812
|
-
|
|||||||||
Other expenses, net
|
172
|
315
|
(143
|
)
|
||||||||
Total research and development expenses
|
$
|
1,458
|
$
|
1,674
|
$
|
(216
|
)
|
Three months ended March 31,
|
||||||||||||
2024
|
2023
|
Change
|
||||||||||
(in thousands)
|
||||||||||||
Occupancy expense
|
$
|
1,901
|
$
|
23
|
$
|
1,878
|
||||||
Payroll-related
|
532
|
357
|
175
|
|||||||||
Professional fees
|
1,285
|
1,935
|
(650
|
)
|
||||||||
Stock-based compensation
|
236
|
625
|
(389
|
)
|
||||||||
Insurance
|
216
|
533
|
(317
|
)
|
||||||||
Other expenses, net
|
145
|
119
|
26
|
|||||||||
Total general and administrative expenses
|
$
|
4,315
|
$
|
3,592
|
$
|
723
|
For the three months ended
March 31,
|
||||||||||||
(in thousands)
|
2024
|
2023
|
Change
|
|||||||||
Cash (used in) provided by:
|
||||||||||||
Operating activities
|
$
|
(3,747
|
)
|
$
|
(6,049
|
)
|
$
|
2,302
|
||||
Investing activities
|
(97
|
)
|
-
|
(97
|
)
|
|||||||
Financing activities
|
1,385
|
-
|
1,385
|
|||||||||
Net decrease in cash and cash equivalents
|
$
|
(2,459
|
)
|
$
|
(6,049
|
)
|
$
|
3,590
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk.
|
Item 4. |
Controls and Procedures.
|
• |
enhancing the business process controls related to reviews over technical, complex, and non-recurring transactions;
|
• |
providing additional training to accounting personnel; and
|
• |
using an external accounting advisor to review management’s conclusions on technical, complex and non-recurring matters.
|
Item 1. |
Legal Proceedings.
|
Item 1A. |
Risk Factors.
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds.
|
Item 3. |
Defaults Upon Senior Securities.
|
Item 4. |
Mine Safety Disclosures.
|
Item 5. |
Other Information.
|
Exhibit
|
Description
|
Incorporated By
Reference
|
|
Inducement Stock Option Award Agreement entered into with Sanjeev Luther
|
Exhibit 99.1 to Form S-8 filed on January 16, 2024
|
||
Employment Agreement, dated as of December 19, 2023, by and among Eterna Therapeutics Inc. and Sanjeev Luther.
|
Exhibit 10.3 to Form 8-K filed on December 20, 2023
|
||
Employment Agreement, effective January 1, 2023, by and among Eterna Therapeutics Inc. and Dorothy Clarke.
|
Exhibit 10.16 to Form 10-K filed on March 14, 2024
|
||
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
||
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
||
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Furnished herewith
|
||
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Furnished herewith
|
||
101.INS
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
|
Filed herewith
|
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
Filed herewith
|
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
Filed herewith
|
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
Filed herewith
|
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
Filed herewith
|
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
Filed herewith
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
|
ETERNA THERAPEUTICS INC.
|
||
Date: May 14, 2024
|
By:
|
/s/ Sanjeev Luther
|
Sanjeev Luther
|
||
President and Chief Executive Officer
|
||
(Principal Executive Officer)
|
||
Date: May 14, 2024
|
By:
|
/s/ Sandra Gurrola
|
Sandra Gurrola
|
||
Senior Vice President of Finance
|
||
(Principal Financial Officer and Principal Accounting Officer)
|